A Review on Melanoma Brain Metastases.

IF 2.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current pharmaceutical design Pub Date : 2025-02-27 DOI:10.2174/0113816128340742250118150157

Sabi Shrestha, Charles M Cook, Jay Parekh, Jane Mattei

引用次数: 0

Abstract

Melanoma brain metastases (MBM) are associated with poor prognosis and remain a significant challenge in oncology. In recent years, significant progress has been made in understanding the molecular mechanisms underlying MBM. Advances in targeted therapies, immunotherapies, and stereotactic radiosurgery (SRS) have significantly improved patient survival. This study presents an overview of the current landscape of treatment approaches and emerging modalities for MBM treatment, highlighting recent advancements and future directions for research and clinical practice.

查看原文本刊更多论文

黑色素瘤脑转移研究进展

黑色素瘤脑转移瘤（MBM）预后不良，是肿瘤学领域的一个重大挑战。近年来，在了解MBM的分子机制方面取得了重大进展。靶向治疗、免疫治疗和立体定向放射手术（SRS）的进展显著提高了患者的生存率。本研究概述了目前MBM治疗方法和新兴模式的概况，重点介绍了研究和临床实践的最新进展和未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current pharmaceutical design 医学-药学

CiteScore

6.30

自引率

0.00%

发文量

302

审稿时长

2 months

期刊介绍： Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.